Literature DB >> 20150363

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.

Victor-Felix Mautner1, Rosa Nguyen, Hannes Kutta, Carsten Fuensterer, Carsten Bokemeyer, Christian Hagel, Reinhard E Friedrich, Jens Panse.   

Abstract

Bilateral vestibular schwannomas are the hallmark of neurofibromatosis type 2 (NF2), and these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the only established treatment, often damages the vestibular nerve. We report 2 cases in which treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced regression of progressive vestibular schwannomas by more than 40% and substantially improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide an effective treatment for progressive vestibular schwannomas in patients with NF2.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20150363      PMCID： PMC2940556          DOI： 10.1093/neuonc/nop010

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


  9 in total

Review 1.  Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.

Authors:  D G R Evans; J M Birch; R T Ramsden; S Sharif; M E Baser
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

2.  Taming glioblastoma: targeting angiogenesis.

Authors:  Eric T Wong; Steven Brem
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

3.  The neuroimaging and clinical spectrum of neurofibromatosis 2.

Authors:  V F Mautner; M Lindenau; M E Baser; W Hazim; M Tatagiba; W Haase; M Samii; R Wais; S M Pulst
Journal:  Neurosurgery       Date:  1996-05       Impact factor: 4.654

4.  Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates.

Authors:  David Mathieu; Douglas Kondziolka; John C Flickinger; Ajay Niranjan; Richard Williamson; Juan J Martin; L Dade Lunsford
Journal:  Neurosurgery       Date:  2007-03       Impact factor: 4.654

5.  Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

Authors:  R M Zuniga; R Torcuator; R Jain; J Anderson; T Doyle; S Ellika; L Schultz; T Mikkelsen
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

6.  Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.

Authors:  Scott R Plotkin; Marybeth A Singh; Caroline C O'Donnell; Gordon J Harris; Andrea I McClatchey; Chris Halpin
Journal:  Nat Clin Pract Oncol       Date:  2008-06-17

7.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Authors:  A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen
Journal:  Neurology       Date:  2008-03-04       Impact factor: 9.910

8.  Multichannel auditory brainstem implant: update on performance in 61 patients.

Authors:  Steven R Otto; Derald E Brackmann; William E Hitselberger; Robert V Shannon; Johannes Kuchta
Journal:  J Neurosurg       Date:  2002-06       Impact factor: 5.115

9.  Expression of VEGF and its receptor genes in intracranial schwannomas.

Authors:  Toshio Uesaka; Tadahisa Shono; Satoshi O Suzuki; Akira Nakamizo; Hiroaki Niiro; Masahiro Mizoguchi; Toru Iwaki; Tomio Sasaki
Journal:  J Neurooncol       Date:  2007-02-14       Impact factor: 4.506
  9 in total
  43 in total

1.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

2.  Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity.

Authors:  Christof Roosli; Fred H Linthicum; Sebahattin Cureoglu; Saumil N Merchant
Journal:  Otol Neurotol       Date:  2012-04       Impact factor: 2.311

3.  mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

Authors:  Marco Giovannini; Nicolas-Xavier Bonne; Jeremie Vitte; Fabrice Chareyre; Karo Tanaka; Rocky Adams; Laurel M Fisher; Laurence Valeyrie-Allanore; Pierre Wolkenstein; Stephane Goutagny; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2014-01-10       Impact factor: 12.300

4.  Antiangiogenic agents for nonmalignant brain tumors.

Authors:  Ammar H Hawasli; Joshua B Rubin; David D Tran; Douglas R Adkins; Shahid Waheed; Timothy E Hullar; David H Gutmann; John Evans; Jeffrey R Leonard; Gregory J Zipfel; Michael R Chicoine
Journal:  J Neurol Surg B Skull Base       Date:  2013-03-13

Review 5.  Neurofibromatosis-related tumors: emerging biology and therapies.

Authors:  Matthias A Karajannis; Rosalie E Ferner
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

6.  Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.

Authors:  Maurits de Vries; Inge Briaire-de Bruijn; Anne-Marie Cleton-Jansen; Martijn J A Malessy; Andel G L van der Mey; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2012-12-08       Impact factor: 4.064

Review 7.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

8.  Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

Authors:  Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Marc S Ballas; Krysten Brown; Annette O Nusbaum; Tsivia Hochman; Judith D Goldberg; Kevin M Koch; John G Golfinos; J Thomas Roland; Jeffrey C Allen
Journal:  Neuro Oncol       Date:  2012-07-27       Impact factor: 12.300

9.  Comparing the sensitivity of linear and volumetric MRI measurements to detect changes in the size of vestibular schwannomas in patients with neurofibromatosis type 2 on bevacizumab treatment.

Authors:  Katrina A Morris; Allyson Parry; Pieter M Pretorius
Journal:  Br J Radiol       Date:  2016-07-25       Impact factor: 3.039

10.  Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.

Authors:  Michael W Ronellenfitsch; Patrick N Harter; Martina Kirchner; Christoph Heining; Barbara Hutter; Laura Gieldon; Jens Schittenhelm; Martin U Schuhmann; Marcos Tatagiba; Gerhard Marquardt; Marlies Wagner; Volker Endris; Christian H Brandts; Victor-Felix Mautner; Evelin Schröck; Wilko Weichert; Benedikt Brors; Andreas von Deimling; Michel Mittelbronn; Joachim P Steinbach; David E Reuss; Hanno Glimm; Albrecht Stenzinger; Stefan Fröhling
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.